Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer

Although early breast cancer (BC) is highly curable, advanced or metastatic disease poses numerous challenges in terms of medical management and treatment decisions and is associated with significantly worse prognosis. Among the new targeted agents, anticancer drugs exploiting the cell-cycle machine...

Descripción completa

Detalles Bibliográficos
Autores principales: Corona, Silvia Paola, Generali, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818877/
https://www.ncbi.nlm.nih.gov/pubmed/29497278
http://dx.doi.org/10.2147/DDDT.S137783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818877/
https://www.ncbi.nlm.nih.gov/pubmed/29497278
http://dx.doi.org/10.2147/DDDT.S137783

Ejemplares similares